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Deep brain stimulation (DBS) surgery has been performed in over 75,000 people worldwide, and 
has been shown to be an effective treatment for Parkinson’s disease, tremor, dystonia, epilepsy, 
depression, Tourette’s syndrome, and obsessive compulsive disorder. We review current and em-
erging evidence for the role of DBS in the management of a range of neurological and psychiat-
ric conditions, and discuss the technical and practical aspects of performing DBS surgery. In the 
future, evolution of DBS technology may depend on several key areas, including better scientific 
understanding of its underlying mechanism of action, advances in high-spatial resolution imaging 
and development of novel electrophysiological and neurotransmitter microsensor systems. Such de-
velopments could form the basis of an intelligent closed-loop DBS system with feedback-guided 
neuromodulation to optimize both electrode placement and therapeutic efficacy.
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Introduction
As a result of both improved technology and understanding 
of neurological diseases, there has been a significant increase 
in the application of restorative functional neurosurgical tech-
niques to treat neuropsychiatric disorders. Among these new-
er surgical therapies, electrical stimulation of specific subcor-
tical brain nuclei, known commonly as deep brain stimulation 
(DBS), has become an increasingly popular alternative to 
pharmacological treatment alone. At this time, more than 
75,000 people have been successfully implanted with DBS de-
vices worldwide, and this number is expected to expand rapid-
ly. DBS is now approved by the US Food and Drug Admin-
istration (FDA) and is in routine clinical use for treatment of, 
Parkinson’s disease (PD),
1 essential tremor (ET),
2-4 dystonia
5 
and obsessive compulsive disorder (OCD).
6,7 Furthermore, 
there is growing evidence for the use of DBS in the treatment 
of disorders such as depression,
8-10 epilepsy,
11-13 Tourette syn-
drome (TS),
14 and chronic pain.
15,16 Here, we review current and 
emerging evidence for the role of DBS in the management of 
a range of neurological and psychiatric conditions, discuss the 
potential mechanism of action, and explore the future applica-
tion of this exciting technology.
Parkinson’s Disease 
PD is associated with a severe loss in function of dopaminer-
gic neuronal cells within the substantia nigra pars compacta 
which project to the striatum, a major component of the basal 
ganglia. Progressive degeneration of these nigrostriatal projec-
tions leads to motor symptoms such as tremor, rigidity, brady-
kinesia, and postural instability. While PD patients have ben-
efited significantly from the development of new pharmaco-
logical treatments used in combination with the traditional 
drug levodopa, many of these therapies have been either only 
partially effective or poorly-tolerated over the long course of 
the disease.
17,18 In addition, these pharmacological therapies 
are also associated with serious and debilitating motor com-
plications, such as dyskinesias.
19 However, significant advanc-
es in stereotactic and functional neurosurgical techniques over 
the last 15 years in response to these shortcomings have led to 
new strategies in the treatment of advanced PD using electri-DBS: Technology at the Cutting Edge
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cal stimulation.
20-22 
Although the therapeutic efficacy of DBS in PD has been 
well-established,
23,24 results from the multicenter, open-label 
PD SURG trial in the UK have shown that DBS plus medical 
therapy improves patient self-reported quality of life signifi-
cantly more than best medical therapy alone.
25 Importantly, 
these findings were accompanied by clinically meaningful dif-
ferences on the Unified Parkinson’s Disease Rating Scale (UP-
DRS), including substantially improved patient ratings of the 
frequency and severity of dyskinesias and “off” periods. 
Today, the most common target for DBS in PD is the subth-
alamic nucleus (STN) as this ameliorates the cardinal symp-
toms of bradykinesia, rigidity and tremor.
24,26,27 In cases of PD 
where the patient’s main complaints do not involve bradykine-
sia or rigidity, other anatomical targets for DBS may be appro-
priate. For example, DBS of the ventralis intermedius (Vim) 
thalamus, which is common for treating ET, is also an effective 
target for patients with tremor-dominant PD.
28-32 As mention-
ed, studies have also demonstrated significant overall impro-
vements in PD patients treated with DBS of the globus palli-
dus interna (GPi).
33-42 Although improvements in both gait and 
posture had been shown,
37,43 the main utility of GPi DBS was 
seen to be in the reduction of dyskinesias often seen with long-
term levodopa treatment.
36-42,44 However, the results of a recent 
multicenter, randomized, blinded trial showed that both GPi 
and STN DBS result in similar improvements in part III (mo-
tor subscale) of the UPDRS at 24 months.
45 Patients who un-
derwent STN DBS subsequently required lower doses of do-
paminergic agents, and the level of depression (as measured 
by the Beck Depression Inventory II) worsened slightly after 
STN stimulation but improved slightly after GPi stimulation, 
although the reported differences are unlikely to be clinically 
important. Recently, interest has also grown in low frequency 
stimulation of the pedunculopontine nucleus for gait disorders/
freezing and postural instability in PD, with two small double-
blinded studies showing a reduction in falls at 1-year.
46,47 
Essential Tremor
ET is characterized by rhythmic, involuntary movements com-
monly affecting the arms, head and voice.
48 It is by far the com-
monest movement disorder, with a prevalence of up to 5.5% 
in those 65 and over.
49 Early promising results for DBS in the 
treatment of ET
50 were replicated and eventually led to a di-
rect comparison study of thalamotomy and DBS of the Vim 
thalamus for treatment of tremors, including ET.
51 In this st-
udy, Schuurman et al.
51 reported a significant improvement of 
tremor in both treatment groups, but a greater reduction in the 
DBS group, who also experienced fewer side effects and a bet-
ter functional outcome. The marked improvement seen with 
DBS of the Vim thalamus for upper limb tremor also appears 
to be maintained during long-term follow-up.
52 
Unfortunately, evidence for the role of thalamic DBS in ET 
affecting the head and voice remains limited apart from some 
small case studies.
53,54
Dystonia
Dystonia refers to a broad group of conditions with differing ae-
tiologies, which involve abnormal muscle spasm and postur-
ing. In general, they may be primary, associated with a genetic 
predisposition such as the torsion dystonia 1 (DYT1) gene, or 
secondary to other causes such as metabolic disorders, drug 
intake (e.g., tardive dyskinesia), or brain injury (e.g., stroke).
55 
Dystonias are also classified as generalized, segmental (affect-
ing two adjacent body parts) or focal (e.g., cervical dystonia/
spasmodic torticollis, blepharospasm, and writer’s cramp) ac-
cording to the pattern of involvement. 
Most evidence for DBS in dystonia highlights the effective-
ness of targeting the GPi in primary generalised dystonia
56,57 
and cervical dystonia. There is also increasing evidence for bi-
lateral GPi DBS in patients with tardive dyskinesia,
58-60 a con-
dition which is notoriously difficult to treat medically. Second-
ary dystonias tend to benefit less from DBS of the GPi, and this 
may be a consequence of the wide range of aetiologies and br-
ain areas potentially involved. 
DBS for Psychiatric Disorders
As highlighted by Kuhn et al.
61 the idea of using DBS to treat 
psychiatric disorders stems from several observations and de-
velopments: 1) some PD patients treated with DBS developed 
psychiatric adverse effects or experienced improvement of a 
co-morbid psychiatric disorder; 2) lesion procedures for in-
tractable psychiatric disorders have yielded positive results, but 
were avoided because of their severe adverse effects; 3) iden-
tification of potential anatomical targets for DBS in psychiat-
ric disorders has improved due to a growing body of function-
al neuroimaging studies. The role of neuromodulation in the 
treatment of refractory psychiatric disorders has been exten-
sively reviewed, including by our own group
62 and more rec-
ently by others.
63 Here, we will only provide an overview of cur-
rent thinking about the role of DBS in treatment-resistant cases 
of depression, OCD and TS.
Depression
In the United States, major depression may affect almost 1 in 
5 people
64 and up to 20% of patients fail to respond to first-line 
pharmacological interventions.
65 Early studies have implicated Shah RS et al.
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the subgenual cingulate cortex (Cg25) in acute sadness and 
antidepressant effects,
66,67 and a decrease in Cg25 activity has 
been associated with immediate clinical response to a number 
of antidepressant treatments including serotonin reuptake in-
hibitors,
68 electroconvulsive therapy,
69 transcranial magnetic 
stimulation,
70 and ablative surgery.
71 As such, early research by 
Mayberg et al.
9 focused on bilateral Cg25 white matter (Cg-
25WM) DBS for treatment-resistant depression and resulted 
in the publication of a preliminary report of six patients
9 and 
a final report of twenty patients.
72 In the final report, after 6 
months 12/20 patients had a reduction of at least 50% in the 
17-item Hamilton Rating Scale for Depression (HRSD-17) 
score and 7 patients met criteria for remission (HRSD-17 ≤7). 
Positron emission tomography (PET) of cerebral blood flow 
(CBF) in the pilot study (5/6 patients) showed increased Cg25 
CBF and decreased CBF in lateral prefrontal and anterior cin-
gulate cortices relative to controls, which reversed with stim-
ulation. Of the additional 14 patients in the final study, 18-Flu-
oro-deoxyglucose-PET (FDG-PET) results from 8 patients res-
ponsive to DBS similarly showed widespread changes in 
cortical and limbic metabolic activity, including increased ac-
tivity in lateral prefrontal cortex and Cg25WM, but a reduc-
tion in Cg25 grey matter. 
Other potential targets relate to areas which the Cg25 sends 
and receives its projections: the nucleus accumbens (NAcc) 
[also referred to as the ventral striatum (VS)] and limbic cor-
tical loop.
73 The NAcc forms an interface between emotional, 
limbic and motor neuronal circuits and plays a vital process-
ing role in the experience of reward and hedonistic stimuli.
61 
In a study by Schlaepfer et al.
10 3 patients with treatment resis-
tant depression underwent bilateral NAcc DBS. Within one 
week of stimulation onset the HRSD-24 decreased by an av-
erage of 42% and demonstrated that stimulation was inverse-
ly correlated with depression. Interestingly, while FDG-PET 
after 1 week of NAcc DBS only showed activation of dorsal 
prefrontal and cingulate cortices (with no change in Cg25 ac-
tivity), subsequently published expanded data for the first 10 
patients
74 showed decreased metabolism in both the Cg25 and 
prefrontal regions on FDG-PET taken at 6 months. In this 
study, 5 patients reached 50% reduction in HRSD-28 at 1 year 
and anxiety was reduced in the whole group, but to a greater 
degree in the responders. 
Previously, studies targeting the ventral anterior internal cap-
sule (VC)/VS treatment-resistant OCD patients have also 
shown improvements in depressive symptoms.
7,75-80 As such, 
Malone et al.
81 attempted bilateral VC/VS DBS in 15 patients 
with treatment-resistant depression. They found that the pro-
portion of patients with at least 50% reduction in HRSD-24 
was 47% at 3 months, 40% at 6 months and 53% at last fol-
low up, while remission rates with HRSD-24 were 20% at 6 
months and 40% at last follow up.
81 
 Obsessive Compulsive Disorder
OCD is characterized by recurring, anxiety-provoking thou-
ghts (obsessions) and repetitive behaviors (compulsions), and 
affects approximately 2% to 3% of the general population.
62,82 
The FDA granted DBS a humanitarian device exemption for 
medically refractory OCD in 2009 on the basis of several clin-
ical trials showing positive findings. As such, the main targets 
currently used for DBS in OCD are the VC/VS,
79 the shell re-
gion of the NAcc, and the STN. 
Early studies showed that bilateral VC/VS DBS had a bene-
ficial impact on OCD symptoms, but required unusually high 
stimulation amplitudes (5.0-10.5 V), suggesting that perhaps 
the therapeutic target was adjacent to, but not at the electrode 
site. Taken together, the high stimulation amplitudes and elec-
trode site (the ventral edge of the internal capsule, where it 
abuts the NAcc) has prompted suggestions that functional bl-
ocking of NAcc activity may be underlying the symptomatic 
improvement.
83 Indeed, a study of unilateral right NAcc DBS 
in 4 patients with refractory OCD showed near complete re-
covery in 3 out of 4 patients using lower stimulation ampli-
tudes (2.0-6.5V).
83 Recently, in a double-blind sham-controll-
ed crossover study of unilateral right NAcc DBS in 10 patients 
with treatment-resistant OCD, Huff et al.
84 reported a full re-
sponse [>35% reduction in Yale-Brown Obsessive Compul-
sive Scale (Y-BOCS)85] in one patient and partial responses (25-
35% reduction in Y-BOCS
85) in 4 other patients at 1 year. Des-
pite a different target and only using unilateral stimulation, these 
results are broadly consistent with earlier studies
7,78,86 where 
about 50-60% of patients acquired a ≥25% reduction in Y-
BOCS score within one year of DBS. While the majority of 
patients in these earlier studies had full responses, Huff et 
al.
84 suggest that this may be due to differences in stimulation 
protocol, anatomical target, use of bilateral stimulation, and ef-
fectiveness of blinding.
In patients with OCD who underwent STN DBS for their 
PD symptoms, studies have also reported unintentional psy-
chiatric benefits.
87,88 In view of this, Mallet et al.
89 performed a 
randomized double-blind crossover study of bilateral antero-
medial STN DBS for treatment-resistant OCD, with two par-
allel groups of 8 patients undergoing two sequential 3-month 
blinded phases (“stimulation on” followed by “stimulation 
off” vs. “stimulation off” followed by “stimulation on”). This st-
udy found a significant reduction in the Y-BOCS score after 
the on-stimulation phase compared to after the sham-stimulat-
ion, but urged caution after observing 15 serious adverse ef-
fects in 11 patients (including one intracerebral haemorrhage 
and 2 infections). DBS: Technology at the Cutting Edge
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Tourette Syndrome
TS is characterized by repetitive, stereotyped, involuntary mo-
vements and vocalizations called tics.
62 These can be simple 
motor tics (e.g., eye blinking, facial grimacing, shoulder sh-
rugging, repetitive throat-clearing), complex tics (combinations 
of movements) and vocal tics such as coprolalia (uttering sw-
ear words) or echolalia (repeating the words or phrases of oth-
ers). The early symptoms of TS are generally noticed in child-
hood, with an average age of onset of 7 to 10 years.
90 Although 
in most cases the disorder is self-limiting or amenable to treat-
ment, some patients have an intractable form which may be 
helped by DBS.
91 
In 1999, DBS was trialed as a new approach for intractable 
TS.
92 Maciunas et al.
14 conducted the first prospective double-
blind crossover trial of DBS in five adults with TS, utilizing 
bilateral stimulation of the centromedian-parafascicular tha-
lamic nuclei (CM-Pf). In the initial 4-week blinded phase pa-
tients spent each week in one of 4 electrode states [no stimu-
lation; unilateral (right-sided) stimulation only; unilateral (left-
sided) stimulation only; bilateral stimulation], followed by 3 
months in the bilateral stimulation state. During the initial bl-
inded phase, a >50% reduction in tics was seen in 3/5 patients 
during the bilateral stimulation week (versus no stimulation) 
as measured by modified Rush Video-Based Rating Scale and 
Yale Global Tic Severity Scale (YGTSS), which fell to 2/5 pa-
tients after 3 months of open stimulation. In another double-
blind, randomized crossover trial 3 patients with medically 
refractory TS were implanted with DBS electrodes in the CM-
Pf and GPi bilaterally (i.e., 4 electrodes per patient).
93 In the 
8-month blinded phase, patients experienced 2 months each 
of CM-Pf, GPi, combined CM-Pf/GPi, and sham stimulation. 
Interestingly, the reduction in the YGTSS was greater during 
bilateral GPi stimulation alone (about 78%) compared to bilat-
eral CM-Pf stimulation (about 45%), and even compared to 
simultaneous CM-Pf/GPi stimulation (about 60%). 
In another uncontrolled study, 18 cases of TS underwent DBS 
placed bilaterally in the CM-Pf and ventralis oralis complex 
of the thalamus.
94 Although follow up ranged from 3-18 mon-
ths, the average YGTSS fell by about 70% after 12 months. 
The same group has recently published the 2-year outcomes 
for 15 of the original 18 patients, which showed a sustained 
reduction in tic severity (about 53%), as well as improvement 
in obsessive-compulsive symptoms, anxiety symptoms, depres-
sive symptoms, and subjective quality of life.
95 
Epilepsy
Approximately 35% of epileptic patients experience refractory 
disease unresponsive to antiepileptic drugs.
96 While some may 
benefit from resective surgery, patients who have seizures ar-
ising from eloquent cortex, or which are multifocal, bilateral, 
or generalized, are not candidates for resective surgery and can 
be considered for alternative therapy.
97 In this context, DBS 
aims to reduce seizures by modulating subcortical systems wh-
ich can remotely control seizure generators. Indeed, previous 
studies have looked at DBS applied to a number of subcorti-
cal targets, including the cerebellum, various thalamic nuclei, 
and several structures of the basal ganglia system (reviewed 
by Kahane and Depaulis
97). However, the recent publication 
of the results from the multicenter, double-blind, randomized 
SANTE trial of bilateral DBS of the anterior thalamic nuclei 
in patients with treatment-resistant partial and secondarily 
generalized epilepsy represents a significant step. This study 
showed a 56% reduction in mean seizure frequency at 2 years 
(n=102), with 54% of patients having at least 50% reduction 
in seizure frequency.
98 While complication rates were modest, 
2 participants had transient stimulation-related seizures and 
during the initial 3 month blinded phase participants in the sti-
mulated group were more likely to report depression and me-
mory problems as adverse effects. 
Chronic Pain
DBS for chronic pain has been used since the 1950s, when the 
caudate and thalamus were targeted in patients with chronic 
pain. However, the lack of conclusive results from multicen-
tre trials
99 undertaken thus far has meant that DBS for pain is 
performed on an off label basis. In a meta-analysis of 7 studies 
published from 1977-1997, which included 424 patients un-
dergoing DBS to the PAG/PVG, internal capsule, and thala-
mus, Bittar et al.
16 found a long term success rate of 79% for 
PAG/PVG compared to only 58% for sensory thalamic stim-
ulation, but 87% when PAG/PVG was combined with sensory 
thalamic/internal capsule stimulation. Interestingly, this is in 
contrast to findings of a recent study of 21 patients receiving ei-
ther ventrocaudalis thalamic nucleus (Vc) or combined Vc and 
PAG/PVG DBS, where of the 5 patients who experienced long-
term pain relief after DBS, 4 had received Vc only DBS.
100 The 
analysis by Bittar et al. also found that patients with failed 
back surgery syndrome (FBSS) had better outcomes than th-
ose with post-stroke pain, phantom limb pain or peripheral 
neuropathic pain, and that nociceptive pain responded to DBS 
better than neuropathic pain. More recently, in a study of 56 
patients with various neuropathic and mixed nociceptive/neu-
ropathic pain syndromes undergoing DBS of the PVG/PAG 
and either VPL or VPM, the best results were again seen in pa-
tients with FBSS, while poorer outcomes were seen for dyses-
thesia dolorosa, phantom limb pain and central pain syndromes 
(spinal cord injury and post-stroke pain).
15 Interestingly, sm-Shah RS et al.
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aller studies by a group in Oxford, UK have had significantly 
better outcomes for phantom limb pain,
101 neuropathic pain
102 
and central pain. Indeed, in a trial of 15 patients with post-st-
roke pain who underwent DBS of the PVG and VPL, it was 
initially successful and devices internalized in 12 patients ex-
hibited a nearly 50% reduction in visual analogue pain score 
over a follow-up period of 27 months.
103
The role of DBS in treating neuropathic and other facial pain 
syndromes has also been studied. Franzini et al.
104 targeted the 
ipsilateral posterior hypothalamus for DBS and reported long-
term pain relief in 5 patients with treatment-resistant cluster 
headache (CH). Subsequently, Schoenen et al.
105 studied ipsi-
lateral ventroposterior hypothalamic DBS in 6 patients with 
intractable CH. Surgery was successfully completed in 4 pa-
tients and, of these, 2 were pain-free and 1 had <3 attacks per 
month, but another only had transient remissions. Long-term 
results of continuous posterior inferior hypothalamic stimu-
lation in 16 chronic drug-refractory patients with CH showed 
that 13 patients were persistently pain-free or almost pain-free, 
and the other 3 are improved at a mean follow-up of 23 mon-
ths.
106 More recently, Green et al.
107 studied DBS of the PAG/
PVG and/or VPM in 7 patients with a range of neuropathic ce-
phalgias of various aetiologies and demonstrated >50% im-
provement in their pain scores. 
DBS Surgical Procedures
All approaches to DBS surgery broadly combine stereotactic 
technique with detailed image guidance. Commonly, a stereo-
tactic head frame is placed on the patient under local anesthe-
sia and magnetic resonance imaging (MRI) is performed to 
identify the anterior commissure, posterior commissure, and 
the mid-commissural point. Well-established Cartesian (x, y, 
and z) target coordinates, relative to the mid-commissural po-
int, are used for planning electrode placement. Stereotactic 
target coordinates are discerned from computer software that 
merges the MRI of the patient’s brain with a brain atlas. At our 
institution, we routinely utilize gadolinium contrast in our pre-
operative MRI with a head frame to visualize the location of 
blood vessels which, in addition to the ventricles, can then be 
avoided in the planned electrode trajectory. 
Once imaging has been completed and a safe trajectory es-
tablished, the patient is returned to the operating room where, 
under sterile conditions and local anesthesia, surgery com-
mences. One or more burr holes are placed in the skull at the 
predetermined entry points. During surgery microelectrode 
unit recordings are used to verify a trajectory using region-spe-
cific neural activity as functional landmarks.
108,109 If suitable re-
sults are not obtained, another tract is chosen, and the record-
ing procedure is repeated. Once a trajectory is verified, the 
microelectrode is withdrawn and the stimulating electrode 
implanted and test stimulation conducted in the awake patient 
using a temporary external stimulator. This enables the patient 
to give verbal feedback confirming the absence of any unwant-
ed side effects from stimulation (e.g., paraesthesias suggesting 
current spread to the somatosensory thalamus) and provides 
the surgeon with an opportunity to relocate the electrode if side 
effects do occur. Confirmation of final electrode position is us-
ually performed first with intraoperative fluoroscopy then po-
stoperative MRI or computed tomography. Once complete 
and trial stimulation is deemed successful, the implanted stim-
ulating electrode is secured to the skull and connected to a pulse 
generator that is subsequently implanted subcutaneously, infe-
rior to the clavicle. 
As such, DBS surgical procedures can be quite lengthy, re-
quiring the awake patient to undergo many difficult hours of 
electrophysiological recordings that is necessary to confirm 
the anatomy scanned by MRI. With each pass of the recording 
microelectrode there is an increased risk of intracranial hem-
orrhage.
110 Even with this extensive and sometimes precarious 
implantation procedure, stimulating electrodes may be mis-
placed, an event associated with side effects such as depres-
sion
111,112 and even suicidal ideation.
112 The state of DBS tech-
nology, the surgical procedures, and post-surgical imaging have 
remained largely static since their inception and remain ardu-
ous and time consuming for both patient and practitioner. As 
such, obtaining optimal lead placement with minimal lead pe-
netrations is of paramount importance and the availability of 
more refined anatomical information to enable more precise 
placement of DBS electrodes, together with utilization of real-
time electrophysiological and neurotransmitter measurements 
during surgery, may address many of these critical issues. How-
ever, it is clear that the framework for the development of the 
next generation of DBS devices and surgical approaches is 
dependent on our understanding of its mechanism of action.
DBS: Potential Mechanisms  
of Action
Despite the bourgeoning application of DBS in clinical prac-
tice, an understanding of the mechanism(s) underlying its cli-
nical effect is incomplete. The similar effectiveness of STN 
DBS and ablative surgery targeting the STN (subthalamoto-
my) initially led to the idea that DBS acted to silence patho-
logically hyperactive neurons
113-116 and this was supported by 
electrophysiological studies.
117,118 Paradoxically, more recent 
studies have reported the activation of STN output nuclei dur-
ing DBS.
119 However, mathematical modeling has reconciled 
these two finding by suggesting that, because of dissimilar ex-
citability of neural elements, soma inhibition and axonal activ-DBS: Technology at the Cutting Edge
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ation are both expected at the DBS electrode site.
120,121 This 
axonal activation hypothesis, which has now come to domi-
nate current thinking
122-125 proposes that DBS evokes changes 
in neural activity and neurochemical transmission in intercon-
nected structures within the basal ganglia complex that ulti-
mately underlie clinical benefit. Unfortunately, our present un-
derstanding of these distal effects of STN DBS remains far 
from complete, in large part because of the technical difficul-
ties in combining available modalities for the global assess-
ment of neural activity with those for the detection of specific 
neurochemicals. 
Consistent with the axonal activation hypothesis, electro-
physiological recordings during STN DBS have shown in-
creased activity in STN target neurons in the GPi and globus 
pallidus externa (GPe)126-128 and the substantia nigra pars re-
ticulata and pars compacta (SNr and SNc, respectively).
129-131 
While definitive, the downside of the electrophysiological ap-
proach is that targets must be selected a priori and few targets 
can be evaluated concurrently. In contrast, brain imaging tech-
niques are ideal candidates for simultaneous global assessment 
of neural activity during STN DBS. 
Several clinical studies utilizing PET, H2
15O-PET, and FDG-
PET support the axonal activation hypothesis of STN DBS.
132 
PET and H2
15O-PET record changes in regional cerebral blo-
od flow (rCBF),
133,134 while FDG-PET measures regional ce-
rebral glucose metabolism.
135 Both rCBF and metabolic activi-
ty are considered to reflect altered local neuronal activity or 
altered input into the region of measurement.
136 In a total of 70 
PD patients using PET
133,137 and H2
15O-PET
132 in the resting st-
ate, studies have found that with clinically effective STN DBS 
there are similar increases in activity in the globus pallidus, 
thalamus, and SN and decreases in activity in the pre-motor 
and supplementary motor areas, including the primary motor 
cortex. Zhao et al.
138 using FDG-PET in seven PD patients 
also found similar increases in activity in basal ganglia struc-
tures, including caudate nucleus and putamen (striatum). Ta-
ken together, these PET results suggest that the net effect of 
STN DBS is to increase the activity of STN output, support-
ing the axonal activation hypothesis.
Clinical studies utilizing functional MRI (fMRI) have also 
supported the axonal activation hypothesis of STN DBS. The 
fMRI brain imaging protocol measures blood-oxygenation-
level dependent (BOLD) contrast
139 that provides in vivo real-
time anatomic maps of blood oxygenation in the brain under 
normal physiological conditions.
140,141 In the first attempt to 
utilize 1.5 Tesla (1.5 T) fMRI in four PD patients during STN 
DBS, Jech et al.
142 showed BOLD signal activation in struc-
tures in the basal ganglia complex such as the globus pallidus, 
thalamus, SN, and cortical structures that included premotor 
cortex and dorsolateral prefrontal cortex. In a more recent 
fMRI study examining the effects of STN DBS, Philips et 
al.
143 implanted five PD patients with bilateral DBS electrodes. 
These investigators reported that BOLD signal activation was 
seen in the ipsilateral basal ganglia, typically in the caudate 
nucleus, putamen and GP in all subjects and ipsilateral thala-
mus in six of the electrodes tested. In another fMRI study of 
one subject the electrode on the left was within the ventral 
STN, whereas the right electrode was in the dorsal STN.
144 The 
left STN DBS primarily showed increases in premotor and 
motor cortex, thalamus, putamen, and cerebellum, as well as de-
creases in sensorimotor/supplementary motor cortex while 
the right DBS showed similar but less extensive change in mo-
tor regions and unique increases in prefrontal cortex, anterior 
cingulate, thalamus, caudate nucleus, and brainstem. Where 
STN DBS effects were specifically examined in PET and fMRI 
studies, they clearly demonstrate that increases in basal gan-
glia network activity (including in the striatum) are consistent 
with the axonal activation hypothesis, but the question of which 
neurotransmitter systems are responsible remains unresolved. 
The dopamine hypothesis
The cardinal symptoms of PD (akinesia, rigidity and tremor) 
are associated with severe nigrostriatal dopaminergic denerva-
tion
145 and levodopa, a biochemical precursor to dopamine and 
the mainstay of PD treatment, is thought to act by increasing 
endogenous dopamine synthesis and release.
146-148 Bilateral 
STN DBS reverses the cardinal motor symptoms in PD pa-
tients,
26,44 and decreases or eliminates the need for levodo-
pa.
149,150 However, the hypothesis that DBS of the STN con-
tributes to symptom relief in PD by activation of surviving ni-
grostriatal dopaminergic neurons, resulting in dopamine rele-
ase and resumption of target cell control in the striatum, is 
still controversial. Indeed, it is entirely possible that STN DBS 
could be altering neuronal circuits downstream of striatal do-
pamine release to provide therapeutic benefit. 
Most basic (animal) studies using in vivo microdialysis, wh-
ich physically removes analyte from brain extracellular fluid 
for ex vivo analysis, do not report an increase in striatal dopa-
mine release during high frequency stimulation (HFS) of the 
STN in intact rats or the 6-hydroxydopamine (6-OHDA)-le-
sioned rat model of PD.
151-153 Additionally, Windels et al.
154,155 
have shown in rats that STN DBS significantly increased glu-
tamate and GABA release in the GPe and SNr, respectively. 
However, the relatively large size of microdialysis probes have 
been shown to disrupt tissue in the immediate vicinity of the 
probe resulting in underestimations of extracellular dopa-
mine levels compared to alternative measurement techniques 
that utilize chemical microsensors.
156-158 As such, approaches 
other than microdialysis will be necessary to assess striatal do-
pamine release during STN DBS. Indeed, chemical microsen-Shah RS et al.
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sors, which offer a smaller probe (5-10 μm versus 200-400 μm 
diameter for microdialysis probes), have shown dopamine 
release in the striatum evoked by STN DBS in the intact and 
6-OHDA rat model
159-161 and in an intact large animal (pig) mo-
del.
162 These latter findings are important on several levels. 
For example, striatal dopamine release during STN DBS has 
been difficult to establish with microdialysis,
151-153,163 with one 
exception,
164 a result that underscores the need for application 
of much smaller microsensors in neurochemical assessments 
of the effects of STN DBS on distal neurotransmission.
Several in vivo PET studies have also failed to demonstrate 
significant displacement of the dopamine receptor ligand [11C] 
raclopride despite significant improvements in motor perfor-
mance following STN DBS,
165-168 potentially suggesting that 
terminal dopamine release does not underlie its anti-Parkinso-
nian effects. However, PET scanning with raclopride has rela-
tively poor temporal resolution and requires an increase of gr-
eater than 90% of baseline measures in order to detect a ch-
ange in dopamine efflux.
166,169 Additionally, it has been sug-
gested that adaptive changes in dopamine receptor populations 
(e.g., D2 receptor internalization and/or recycling) occurring 
over long-term STN stimulation may interfere with PET quan-
tification of dopamine release in these patients.
170 However, 
the fact that DBS of the STN is most effective in PD patients 
who respond well to levodopa
171 and contraindicated for those 
who do not,
172 suggests that effective DBS requires endoge-
nous dopamine production. Additionally, the observations that 
DBS elicits dyskinesias that resemble those seen with levodo-
pa excess
26 and that, like levodopa, it contributes to impul-
sivity (a behavior thought to be dopamine-mediated)173 are 
also consistent with activation of surviving dopaminergic neu-
rons by DBS. Thus, whether STN DBS improves PD symp-
toms via the release of dopamine remains an important but un-
answered question.
Adenosine, glutamate, and glia
Another putative neurochemical that may be of importance 
to STN DBS mechanisms is adenosine. Proposed as a chemi-
cal mediator of thalamic DBS for the treatment of ET,
174 ade-
nosine release can be measured in the striatum with chemical 
microsensors during electrical stimulation in the vicinity of 
the nigrostriatal dopaminergic tract.
175,176 Importantly, increas-
es in extracellular adenosine appear to match elevations in 
CBF resulting from increases in neural activity.
177 Indeed, we 
have demonstrated that STN DBS elicits adenosine release 
in the striatum as measured by chemical microsensors.
178 Ade-
nosine is also known to play a role in astrocyte signaling and 
this fact may become even more important in view of grow-
ing interest in the local effects of DBS on glial cells.
174,179,180
Glial cells far outnumber neurons in the brain and have, in 
recent years, been shown to play an active role in synaptic com-
munication.
181 This tripartite synapse hypothesis (involving 
pre- and post-synaptic neuronal elements and glia) has caused 
a paradigm shift in how we approach the study of neurotrans-
mitter release and action on neural network function (see re-
view by Perea and Araque
182). There is now evidence to sug-
gest that DBS activates glial cells directly to elicit release of 
gliotransmitters that, in turn, have widespread effects on the 
tripartite synapse and the neuronal network. As opposed to the 
previously presumed local inhibitory action of DBS at the site 
of stimulation, the prevailing effect appears to be excitation of 
both glial and neuronal elements and subsequent changes in 
neural network activity. Despite growing acceptance of this 
general scheme, the underlying questions of what elements 
are affected, how they are affected, and which neurotransmit-
ters mediate these changes, remain largely unanswered.
It is well-documented that HFS modulates astrocyte activi-
ty by triggering the onset of a propagating Ca
2+ wave.
183-185 In 
fact, initial studies of astrocyte-neuronal interactions used elec-
trical stimulation to evoke long-distance Ca
2+ signaling
186 and 
it is well known that electrical stimulation of brain tissue re-
sults in glial activation to increase intracellular cytosolic Ca
2+ 
concentrations.
187 Moreover, this local activation of glia can 
lead to a wave of Ca
2+ influx that propagates through the glial 
cell syncytium in the brain for distances as great as several cen-
timeters.
187,188 Astrocytic Ca
2+ increases, in turn, evoke the re-
lease of gliotransmitters, including ATP/adenosine, glutamate, 
D-serine, and PGE2.
189-191 Release of these gliotransmitters can 
result in excitation or inhibition of neurons as well as the mo-
dulation of synaptic transmission and synaptic plasticity.
181,186,192,193
Several studies have now established that astrocytes contain 
vesicular glutamate stores that can be triggered to undergo ex-
ocytosis by mechanical stimulation,
194 in turn activating iono-
tropic
195 or metabotropic glutamate receptors.
196 In a similar 
manner, HFS of hippocampal slices or astrocyte cultures can 
elicit astrocytic Ca
2+ waves.
193,197 Astrocytes also release glu-
tamate through volume-sensitive channels after ATP stimula-
tion.
198 This implies that specific stimuli may recruit different 
gliotransmitter release mechanisms to modify the spatio-tem-
poral characteristics of subsequent neuronal responses. These 
and other studies have pointed to glutamate and adenosine as 
key mediators of astrocyte-to-neuron signaling.
199 Astrocytes 
have also been implicated in mediating heterosynaptic depres-
sion, through the release of ATP and its subsequent catabolism 
to adenosine.
174,200-202 Most notably, astrocytes respond to neu-
ronal activity with waves of Ca
2+ influx,
203,204 which in turn eli-
cit further glutamate release.
205 Thus, DBS-induced Ca
2+ sig-
naling in astrocytes may affect neuronal network activity th-
rough gliotransmitter release, thereby playing an important 
role in the therapeutic mechanism of DBS. DBS: Technology at the Cutting Edge
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DBS applied to the area containing tremor cells leads to im-
mediate tremor arrest, an effect that is rapidly reversed when 
stimulation ceases.
206 Similarly, we and others have demon-
strated that DBS of the thalamus
207,208 and STN
209 results in neu-
rotransmitter release, including glutamate. In our experimen-
tal condition, HFS applied to the thalamus led to immediate 
glutamate and adenosine release, which decreased to pre-stim-
ulation levels when stimulation ceased.
180 Thus, HFS-mediat-
ed glutamate and adenosine release may be important in the 
ability of DBS to abolish synchronized neural network oscil-
lations such as those seen in tremor and seizures. Important-
ly, Bekar et al.
174 have shown that thalamic DBS is associated 
with a marked increase in the local efflux of ATP and extracel-
lular accumulation of its catabolic product, adenosine, which 
can act as a neuromodulator. Together, these findings suggest 
that DBS may activate multiple neurotransmitter systems, in-
cluding glutamate and adenosine. Which of these neurotrans-
mitter systems is primarily responsible for the effects of DBS 
in human patients and whether they are glial or neuronal in ori-
gin requires further investigation.
We and others contend that characterization of the hitherto 
understudied glial effects of DBS on neurotransmission will 
provide a deeper understanding of its corrective actions on 
dysfunctional brain processing, and consequently enhance our 
capacity to utilize its therapeutic effects in the patient.
174,180 
This basic knowledge will substantially enhance our poten-
tial to further develop DBS technology and surgical proce-
dures to produce significant improvement in patient outcome. 
In particular, an integrative approach will be important in de-
fining the causal relationships between DBS-mediated glial 
activation and neural network activity within the thalamus.
New Directions in DBS Therapy
To address the scientific and clinical issues outlined so far, it 
is clear that more sophisticated brain imaging and real-time 
in vivo electrophysiological and neurochemical monitoring 
techniques will be essential to mechanistic studies of DBS ac-
tion, optimizing electrode placement during surgery and in the 
future development of intelligent, closed-loop DBS systems. 
As such, we will now explore these areas in turn and outline th-
eir potential roles in the evolution of DBS therapy in the future.
Optimizing electrode placement
Recent advances have dramatically increased the magnetic 
field strength for MRI, and prototype research systems have 
been fitted with 7.0 T magnets, which are five-times the streng-
th of the typical 1.5 T machines currently used in most hospi-
tals. High-contrast and high-resolution brain images can thus 
be obtained with an ultra high-field MRI system to provide 
details never before observed in the living human brain.
210-212 
Fig. 1 shows sagittal and coronal images collected by 7.0 T MRI. 
The detailed brain structures, in particular, the high contrast 
visualization of the STN, should improve the accuracy of de-
termining stereotactic coordinates for positioning stimulation 
electrodes during DBS surgery.
213
In addition to imaging, counter-localization of the target 
electrode site is currently performed using microelectrode elec-
Fig. 1. Sagittal (A) and coronal (B) images obtained by 7.0 T MRI using a brain-optimized sensitivity encoding coil. Areas shown are the most 
complex areas in the brain with numerous nuclei readily visible, including subthalamic nucleus (STN), substantia nigra (SN), claustrum (Cl), 
putamen (Pu), globus pallidus externa and interna (GPe and GPi), posterior cerebral artery (PCA), third ventricle (3V), and hippocampus 
(HC) among others. 
A   B   7.0 T MR Sagittal View Image 7.0 T MR Coronal View ImageShah RS et al.
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trophysiological recordings, but in the future this may be op-
timized by real-time neurochemical monitoring modalities (dis-
cussed below) together with analysis of local electrophysio-
logical parameters. In terms of the latter, recently Zaidel et 
al.
214 in a study of 128 PD patients have shown that optimal 
clinical outcome of bilateral STN DBS is correlated with place-
ment of the electrode within a distinct dorsolateral oscillatory 
region of the STN (characterized by increased β-oscillatory 
activity on multi-unit recordings), rather than simply at its an-
atomical centre. 
Importantly, another group have shown the benefits of sub-
sequently tailoring stimulation parameters according to the 
final position of the DBS electrode. In the studies by Paek et 
al.
215 and Lee et al.
216 pre-operative 1.5 T MRI images were fus-
ed with either post-operative MRI (at 3 and 6 months) and 
post-operative CT (at 6 months) scans respectively and the 
three-dimensional anatomical location of electrode contacts 
used to re-program stimulation parameters. In both studies, 
there was a significant improvement in UPDRS-III motor sub-
scale (in both on- and off-medication states) and reduction in 
medication requirements. 
Finally, measuring the latency of saccadic eye movements 
in the conscious patient (saccadometry) may also facilitate 
optimal electrode targeting. Temel et al.
217 have shown that sac-
cadic latency is a sensitive and objective measure of the ther-
apeutic effect of STN DBS and it correlates well with the UP-
DRS-III. In the future, this could form the basis of another qu-
antitative mode of intra-operative guidance for electrode pla-
cement in the STN. 
Wireless monitoring of in vivo neurotransmitter 
release
Microdialysis and voltammetry are the two most widely used 
techniques for neurochemical monitoring in vivo.
218,219 How-
ever, recording from the basal ganglia complex during clinical-
ly-relevant DBS of the STN requires a degree of temporal and 
spatial sampling analysis that voltammetric techniques easily 
provide over conventional microdialysis procedures (i.e., sub-
second time scales and μm-sized space domains
220). For our 
own aims of examining the functional anatomical and neuro-
chemical effects of STN DBS, we developed the Wireless In-
stantaneous Neurotransmitter Concentration System (WIN-
CS)-a device designed specifically to monitor neurochemical 
release during experimental and clinical DBS surgery. As such, 
research subject safety, signal fidelity, and integration with ex-
isting DBS surgical procedures, and now MRI pre-, intra, and 
postoperative analysis, have been key priorities during the de-
velopment of WINCS. Additionally, it is easily attached to the 
stereotactic frame and transmits neurochemical release data to 
a remotely located base station (within 10 m), thus facilitating 
recording parameter settings and data acquisition, while mi-
nimizing encumbrance of personnel and equipment at the op-
erating/recording site. 
The WINCS device, designed in compliance with FDA-
recognized consensus standards for medical electrical device 
safety, consists of a relatively small, wireless, sterilizable bat-
tery-powered unit that can interface with carbon-fiber micro-
electrodes (CFM) or enzyme-based microsensors for real-time 
monitoring of neurotransmitter release in mammalian brain.
221-223 
Indeed, our own work in pigs has utilized fast scan cyclic vol-
tammetry (FSCV) and CFMs to evaluate neurotransmission 
within the basal ganglia during STN DBS. Briefly, FSCV em-
ploys a linearly scanned potential (V) applied at 100 ms inter-
vals to brain-implanted CFMs and compared to an Ag/AgCl re-
ference electrode in contact with the cortical surface of the 
brain. This detection scheme generates a voltammogram (a 
plot of measured oxidation and reduction current versus the 
applied potential) that provides a signature to identify the re-
corded chemical (Fig. 2). Changes in the amplitude of the 
oxidation peak recorded by FSCV thus provide a quantitative 
concentration measurement of the temporal effects of electri-
cal stimulation on neurochemical release. Neurotransmitters 
and neuromodulators amenable to detection by FSCV include 
dopamine, serotonin, norepinephrine, adenosine, and nitric 
oxide.
157,178,220,224-229 
For our DBS studies, the WINCS device has significant ad-
vantages over other commercially available wireless recording 
systems as it offers 1) an advanced microprocessor with supe-
rior analog to digital conversion, greater internal memory, and 
faster clock speed, 2) wirelessly programmable waveform pa-
rameters (scan bias, range and rate) using an advanced Blue-
tooth
® module for wireless communication, 3) a higher precis-
ion voltage reference for the micro-processor, 4) a low-power 
mode to preserve battery life, voltage sensing, and low-power 
alert, and most importantly 5) proven compatibility and func-
tionality in the bore of an MRI during image acquisition. The 
engineered compatibility of WINCS with MRI offers a unique 
opportunity to quantify regional variations in neurotransmis-
sion by FSCV during fMRI procedures opening up exciting 
and novel research directions that go well beyond investiga-
tions of central DBS mechanisms. 
Intelligent closed-loop DBS devices
DBS in its current open-loop form is always on and not guid-
ed by any changes in underlying brain activity related to the 
disorder being treated. However, given that the brain commu-
nicates both electrically and chemically, it is likely that the 
most effective treatments for many neurological and psychiat-
ric disorders will, in the future, involve returning both electri-
cal firing patterns and neurotransmitter release levels back to DBS: Technology at the Cutting Edge
176  J Clin Neurol 2010;6:167-182
normal.
230 NeuroPace (Mountain View, CA, USA) have devel-
oped a closed-loop responsive neurostimulation (RNS
®) de-
vice for the treatment of refractory partial epilepsy that uses 
cortical surface (subdural) or depth electrodes sited at the seizure 
focus to monitor for abnormal electrical activity in order to elicit 
a pre-programmed normalizing burst of stimulation to prevent 
seizure onset. Alternatively, oscillations in the electrical field im-
mediately around (and recorded using) DBS electrodes which 
reflect synchronized activity of large populations of neurons, ter-
med local field potentials, have also been proposed as feedback 
sources for online adjustment of DBS parameters.
231,232 
While the ability to undertake intra- and post-operative neu-
rochemical monitoring will be crucial in the short-term for 
testing predictions of the neurotransmitter release (synaptic 
modulation) hypothesis of DBS, in the long-term it too may 
form a blueprint for a closed-loop DBS device supporting all-
in-one neuromonitoring and neuromodulation. Conceivably, 
a neuroprosthesis supporting real-time, instantaneous neuro-
chemical sensing and feedback-guided adjustment of stimu-
lation to maintain therapeutic neurotransmitter levels would 
be superior to drug treatments for neuropsychiatric disorders 
that entail onset and offset effects. Indeed, we have initiated 
work towards the ultimate realization of a closed-loop smart 
DBS device utilizing this rationale. One critical component 
is an ultra-small, low-power integrated circuit supporting wi-
reless neurochemical monitoring. By using very-large-scale-
integration techniques in standard complementary-metal-ox-
ide-semiconductor technology, we have been able to fabricate 
a wireless device, with dimensions of 2.2×2.2 mm, support-
ing single-channel FSCV. Indeed, this device compared fa-
vorably to a conventional hardwired system in calibration tests 
in vitro and for measuring electrical stimulation-evoked do-
pamine levels in the anesthetized rat.
233 
Conclusion
DBS is now a widely accepted and efficacious therapy for 
many conditions, but we still lack a definitive understanding 
of its mechanism of action. Indeed, while the nature of DBS 
devices make them amenable to blinded trials aimed at test-
ing the efficacy of HFS in emerging clinical contexts, future 
paradigm shifts in DBS technology and the movement to-
wards closed-loop devices undoubtedly rest on our ability to 
gain a clearer understanding of the mechanisms responsible 
Fig. 2. Plots showing wireless detection of adenosine using WINCS at a CFM in vitro. A: Pseudocolor plot obtained during a 20 second flow cell 
injection of 5 μM adenosine, exhibiting 3D information. The x axis, y axis, and color gradient indicate time, voltage applied at the CFM, and cur-
rent (I) detected from the CFM, respectively. The FSCV waveform was applied from -0.4 V to +1.5 V and back to -0.4 V at 400 V/second every 
100 msec. A green oval surrounded by a purple ring first appears around +1.5 V after the adenosine injection, and this represents the first oxi-
dative peak of adenosine. A second oxidative peak around +1.0 V occurs after the appearance of the first oxidative peak. B: Graph showing cur-
rent versus time traces for the first and second peak oxidative currents (taken along horizontal black and red dotted lines respectively on 2A). 
C: A representative background-subtracted folded voltammogram of adenosine, showing 1st and 2nd oxidative peaks (taken along vertical 
solid black line in 2A). D: Picture of the WINCS device chipset relative to a United States quarter dollar coin. WINCS: Wireless Instantaneous 
Neurotransmitter Concentration System, CFM: carbon-fiber microelectrodes, FSCV: fast scan cyclic voltammetry. 
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for the clinical effect of DBS. Fortunately, it appears that the 
same technological advances demanded by basic science in-
vestigators may also turn out to be central to the design of fu-
ture intelligent DBS systems used by clinicians. 
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